139 related articles for article (PubMed ID: 35533035)
21. An open-label tolerability and efficacy study of an aluminum sesquichlorohydrate topical foam in axillary and palmar primary hyperhidrosis.
Innocenzi D; Ruggero A; Francesconi L; Lacarrubba F; Nardone B; Micali G
Dermatol Ther; 2008 Jul; 21 Suppl 1():S27-30. PubMed ID: 18727813
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of methantheline bromide (Vagantin(®) ) in axillary and palmar hyperhidrosis: results from a multicenter, randomized, placebo-controlled trial.
Müller C; Berensmeier A; Hamm H; Dirschka T; Reich K; Fischer T; Rzany B
J Eur Acad Dermatol Venereol; 2013 Oct; 27(10):1278-84. PubMed ID: 23004926
[TBL] [Abstract][Full Text] [Related]
23. [Botulinum toxin in the treatment of focal hyperhidrosis].
Schnider P; Moraru E; Kittler H; Voller B; Kranz G; Auff E
Wien Klin Wochenschr; 2001; 113 Suppl 4():36-41. PubMed ID: 15506051
[TBL] [Abstract][Full Text] [Related]
24. Urinary retention and mydriasis secondary to topical glycopyrronium for axillary hyperhidrosis.
Green HH; Ray L; Buchanan J; Matsler N
Am J Health Syst Pharm; 2023 Sep; 80(18):1234-1237. PubMed ID: 37348110
[TBL] [Abstract][Full Text] [Related]
25. Pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for treatment of axillary hyperhidrosis.
Baumann L; Slezinger A; Halem M; Vujevich J; Martin LK; Black L; Bryde J
Int J Dermatol; 2005 May; 44(5):418-24. PubMed ID: 15869543
[TBL] [Abstract][Full Text] [Related]
26. Botulinum toxin type a is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study.
Naumann M; Lowe NJ; Kumar CR; Hamm H;
Arch Dermatol; 2003 Jun; 139(6):731-6. PubMed ID: 12810503
[TBL] [Abstract][Full Text] [Related]
27. Safety and prolonged efficacy of Botulin Toxin A in primary hyperhidrosis.
D'Epiro S; Macaluso L; Salvi M; Luci C; Mattozzi C; Marzocca F; Salvo V; Scarnò M; Calvieri S; Richetta AG
Clin Ter; 2014; 165(6):e395-400. PubMed ID: 25524193
[TBL] [Abstract][Full Text] [Related]
28. Thoracoscopic sympathectomy for palmar and axillary hyperhidrosis: four-year outcome and quality of life after bilateral 5-mm dual port approach.
Bachmann K; Standl N; Kaifi J; Busch P; Winkler E; Mann O; Izbicki JR; Strate T
Surg Endosc; 2009 Jul; 23(7):1587-93. PubMed ID: 19259731
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of Miniuniportal Video-Assisted Thoracoscopic Selective Sympathectomy (Ramicotomy) for the Treatment of Severe Palmar and Axillar Hyperhidrosis.
Akil A; Semik M; Fischer S
Thorac Cardiovasc Surg; 2019 Aug; 67(5):415-419. PubMed ID: 29739022
[TBL] [Abstract][Full Text] [Related]
30. A Prospective, Nonrandomized, Open-Label Study of the Efficacy and Safety of OnabotulinumtoxinA in Adolescents with Primary Axillary Hyperhidrosis.
Glaser DA; Pariser DM; Hebert AA; Landells I; Somogyi C; Weng E; Brin MF; Beddingfield F
Pediatr Dermatol; 2015; 32(5):609-17. PubMed ID: 26059781
[TBL] [Abstract][Full Text] [Related]
31. Treatment of focal hyperhidrosis with botulinum toxin type A: long-term follow-up in 61 patients.
Schnider P; Moraru E; Kittler H; Binder M; Kranz G; Voller B; Auff E
Br J Dermatol; 2001 Aug; 145(2):289-93. PubMed ID: 11531794
[TBL] [Abstract][Full Text] [Related]
32. Botulinum toxin type A and B improve quality of life in patients with axillary and palmar hyperhidrosis.
Rosell K; Hymnelius K; Swartling C
Acta Derm Venereol; 2013 May; 93(3):335-9. PubMed ID: 23053164
[TBL] [Abstract][Full Text] [Related]
33. CT-Guided, Ethanol Sympatholysis for Primary Axillary-Palmar Hyperhidrosis.
Tsitskari M; Friehs G; Zerris V; Georgiades C
Cardiovasc Intervent Radiol; 2016 Dec; 39(12):1722-1727. PubMed ID: 27460257
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of hyperhidrosis by topical application of a local anesthetic composition.
Juhlin L; Evers H; Broberg F
Acta Derm Venereol; 1979; 59(6):556-9. PubMed ID: 94225
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of botulinum toxin type B for the treatment of primary palmar hyperhidrosis: a prospective, open, single-blind, multi-centre study.
Basciani M; Di Rienzo F; Bizzarrini M; Zanchi M; Copetti M; Intiso D
Arch Dermatol Res; 2014 Jul; 306(5):497-503. PubMed ID: 24522897
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of topical glycopyrrolate in patients with facial hyperhidrosis: a randomized, multicentre, double-blinded, placebo-controlled, split-face study.
Hyun MY; Son IP; Lee Y; Choi HG; Park KY; Li K; Kim BJ; Seo SJ; Kim MN; Hong CK
J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):278-282. PubMed ID: 24909188
[TBL] [Abstract][Full Text] [Related]
37. Pharmacologic anisocoria secondary to topical glycopyrronium for axillary hyperhidrosis: an emerging clinical presentation.
Kaufman AR; Gulati S; Curnyn KM
Can J Ophthalmol; 2020 Oct; 55(5):464. PubMed ID: 32735775
[No Abstract] [Full Text] [Related]
38. Mydriasis and anisocoria in a pediatric hyperhidrosis patient with interesting findings in the family cat.
Sandhu M; Eisenstein K
Pediatr Dermatol; 2023 Jan; 40(1):210-211. PubMed ID: 36263444
[TBL] [Abstract][Full Text] [Related]
39. Treatment of Axillary Bromhidrosis with Topical 2% Glycopyrronium Bromide Cream: A Prospective, Non-randomized, Open-label Study.
Gregoriou S; Markantoni V; Campanati A; Martina E; Offidani A; Kouris A; Platsidaki E; Bokotas H; Stratigos A; Rigopoulos D; Kontochristopoulos G
J Clin Aesthet Dermatol; 2021 Nov; 14(11):E61-E63. PubMed ID: 34980961
[TBL] [Abstract][Full Text] [Related]
40. A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis.
Wolosker N; de Campos JR; Kauffman P; Puech-Leão P
J Vasc Surg; 2012 Jun; 55(6):1696-700. PubMed ID: 22341836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
